Stem Cell Therapy from Blood: The Basics

Patients may undergo a blood-based (venous) stem cell therapy. This purely blood-derived therapeutic option is less invasive. The venous stem cell therapy has proven effective in combating chronic lung disease. For optimal results, follow-up therapies may need to be performed more often.

Stem Cell Therapy from Blood: The Procedure

The venous stem cell procedure is performed in a clinical outpatient setting over the course of three days. After the Lung Institute’s medical staff has determined that a patient is a candidate for venous stem cell therapy, he or she will be asked to fill out all of the required paperwork and necessary forms. An electrocardiogram (EKG) and pulmonary function test will be performed, and the patient will go through a preparation process to stimulate stem cell production within the body. Following the insertion of an IV, the autologous hematopoietic stem cells are harvested, washed, isolated and returned to the patient’s body intravenously where they can begin restoring the patient’s lungs. This process is repeated on days two and three of the patient’s therapy program. This minimally invasive procedure has proven to be a viable option for many patients with chronic obstructive pulmonary disease (COPD). At the end of day three, the overseeing physician will do a thorough final evaluation of the patient’s stem cell therapy and prep him or her for follow-up care.

Blood-derived Stem Cell Therapy Follow-Up Care

The patient will receive follow up care two weeks, three months and six months following his or her therapy. The patient is encouraged to return for a follow-up appointment with his or her pulmonologist at the three-month mark.

If you would like to find out more about our available therapy options, please contact one of our patient care coordinators today at (800) 729-3065 to schedule a free consultation.


* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.